Cargando…

Whole-Body Pharmacokinetics and Physiologically Based Pharmacokinetic Model for Monomethyl Auristatin E (MMAE)

Monomethyl auristatin E (MMAE) is one of the most commonly used payloads for developing antibody–drug conjugates (ADC). However, limited studies have comprehensively evaluated the whole-body disposition of MMAE. Consequently, here, we have investigated the whole-body pharmacokinetics (PK) of MMAE in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Hsuan Ping, Cheung, Yuen Kiu, Shah, Dhaval K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004929/ https://www.ncbi.nlm.nih.gov/pubmed/33807057 http://dx.doi.org/10.3390/jcm10061332

Ejemplares similares

Tumor-Specific Monomethyl Auristatin E (MMAE) Prodrug Nanoparticles for Safe and Effective Chemotherapy
por: Cho, Hanhee, et al.
Publicado: (2022)

Pharmacokinetic and Metabolism Studies of Monomethyl Auristatin F via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry
por: Park, Min-Ho, et al.
Publicado: (2019)

Monomethyl Auristatin E Grafted-Liposomes to Target Prostate Tumor Cell Lines
por: Abawi, Ariana, et al.
Publicado: (2021)

Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates
por: Fu, Zhiwen, et al.
Publicado: (2023)

Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E
por: Wang, Yichen, et al.
Publicado: (2018)

Light-Activated Monomethyl Auristatin E Prodrug Nanoparticles for Combinational Photo-Chemotherapy of Pancreatic Cancer
por: Cho, In Kyung, et al.
Publicado: (2022)

New insight on the structural features of the cytotoxic auristatins MMAE and MMAF revealed by combined NMR spectroscopy and quantum chemical modelling
por: Johansson, Mikael P., et al.
Publicado: (2017)

Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload
por: Wang, Yanming, et al.
Publicado: (2017)

Fibroblast Growth Factor 2 Conjugated with Monomethyl Auristatin E Inhibits Tumor Growth in a Mouse Model
por: Krzyscik, Mateusz A., et al.
Publicado: (2021)

Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy
por: Hingorani, Dina V., et al.
Publicado: (2022)

A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo
por: Gallery, Melissa, et al.
Publicado: (2018)

Bombesin-Tethered Reactive Oxygen Species (ROS)-Responsive Nanoparticles for Monomethyl Auristatin F (MMAF) Delivery
por: Kim, Jihoon, et al.
Publicado: (2021)

Purification and In Vitro Evaluation of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Cancer Cells
por: Damiani, Isabella, et al.
Publicado: (2021)

Halogenation at the Phenylalanine Residue of Monomethyl Auristatin F Leads to a Favorable cis/trans Equilibrium and Retained Cytotoxicity
por: Sokka, Iris K., et al.
Publicado: (2021)

Cytotoxic Conjugates of Fibroblast Growth Factor 2 (FGF2) with Monomethyl Auristatin E for Effective Killing of Cells Expressing FGF Receptors
por: Krzyscik, Mateusz Adam, et al.
Publicado: (2017)

Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells
por: Liu-Kreyche, Peggy, et al.
Publicado: (2019)

Synthesis and Biological Evaluation of RGD and isoDGR–Monomethyl Auristatin Conjugates Targeting Integrin α(V)β(3)
por: Raposo Moreira Dias, André, et al.
Publicado: (2019)

Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera(®) (Dimethyl Fumarate)
por: Lategan, Thomas W., et al.
Publicado: (2021)

Synthesis and Evaluation of a Monomethyl Auristatin E—Integrin α(v)β(6) Binding Peptide–Drug Conjugate for Tumor Targeted Drug Delivery
por: Davis, Ryan A., et al.
Publicado: (2023)

Physiologically-based pharmacokinetic model for pulmonary disposition of protein therapeutics in humans
por: Jagdale, Prabhas, et al.
Publicado: (2022)

Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
por: Zhou, Wei, et al.
Publicado: (2023)

Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals
por: Schlender, Jan-Frederik, et al.
Publicado: (2016)

Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes
por: Chang, Hsuan-Ping, et al.
Publicado: (2023)

FGF2 Dual Warhead Conjugate with Monomethyl Auristatin E and α-Amanitin Displays a Cytotoxic Effect towards Cancer Cells Overproducing FGF Receptor 1
por: Świderska, Karolina Weronika, et al.
Publicado: (2018)

Predicting Paclitaxel Disposition in Humans With Whole‐Body Physiologically‐Based Pharmacokinetic Modeling
por: Fu, Qiang, et al.
Publicado: (2019)

Physiologically‐based pharmacokinetic model of vaginally administered dapivirine ring and film formulations
por: Kay, Katherine, et al.
Publicado: (2018)

Bivalent EGFR-Targeting DARPin-MMAE Conjugates
por: Karsten, Lennard, et al.
Publicado: (2022)

A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim
por: Niederalt, Christoph, et al.
Publicado: (2017)

Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy
por: Yao, Hang-Ping, et al.
Publicado: (2019)

Pharmacokinetics of Monoclonal Antibody and Antibody Fragments in the Mouse Eye Following Systemic Administration
por: Bussing, David, et al.
Publicado: (2021)

Old Drug, New Delivery Strategy: MMAE Repackaged
por: Lahnif, Hanane, et al.
Publicado: (2023)

Correction to: Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy
por: Yao, Hang-Ping, et al.
Publicado: (2019)

Predictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in Children
por: Zhou, W, et al.
Publicado: (2016)

Utility of a single adjusting compartment: a novel methodology for whole body physiologically-based pharmacokinetic modelling
por: Ando, Hirotaka, et al.
Publicado: (2008)

Dual-Warhead Conjugate Based on Fibroblast Growth Factor 2 Dimer Loaded with α-Amanitin and Monomethyl Auristatin E Exhibits Superior Cytotoxicity towards Cancer Cells Overproducing Fibroblast Growth Factor Receptor 1
por: Nawrocka, Daria, et al.
Publicado: (2023)

Quantification of a Novel Photosensitizer of Chlorin e6-C15-Monomethyl Ester in Beagle Dog Plasma Using HPLC: Application to Pharmacokinetic Studies
por: Li, Xiuxiu, et al.
Publicado: (2017)

Guanidine-modified albumin-MMAE conjugates with enhanced endocytosis ability
por: Yi, Ce, et al.
Publicado: (2023)

Unraveling bisphenol A pharmacokinetics using physiologically based pharmacokinetic modeling
por: Yang, Xiaoxia, et al.
Publicado: (2015)

Pharmacokinetic Characterization of Supinoxin and Its Physiologically Based Pharmacokinetic Modeling in Rats
por: Song, Yoo-Kyung, et al.
Publicado: (2021)

Physiologically based pharmacokinetic modeling for predicting irinotecan exposure in human body
por: Fan, Yingfang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_h8fd7qk94hdo9d8dnpjnrij2ci